Shots:

• Goldfinch to be responsible for all WW development & commercialization activities of GFB-024. Takeda to get an option to sub-license rights of GFB-024- prior to the initiation of the pivotal studies in Japan
• Goldfinch to utilize its biology platform and Kidney Genome AtlasTM to develop GFB-024. Additionally- its GFB-887 (TRPC5 inhibitor) is being evaluated in P-I study for focal segmental glomerulosclerosis
• GFB-024 is a CB1 inhibitor with its preclinical data supporting the inhibition of CB1 signaling as a novel treatment of diabetic nephropathy and obesity-related glomerulopathies with its expected initiation of P-I study in H2’20

Click here to­ read full press release/ article 

 Ref: Goldfinch Bio | Image: Takeda